Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Team Grant: Mental Disorders

University of Toronto

$224,880.00

Role of genetic polymorphisms in drug metabolizing cytochrome P450 enzymes expressed in the brain for affective disorders

FY 2013-14

Summary
Cytochrome P450 (CYP) enzymes are an important class of drug metabolising enzymes, proteins that help eliminating external substances such as drugs or toxins that have been ingested or absorbed by the organism as well substances that are produced by the organism itself (endo¬genous substrates). Several findings suggest that two CYP enzymes, CYP2C19 and CYP2D6 have endogenous substrates, are in the brain, and may play directly a role in the genesis and course of affective illness, but as yet we do not know precisely what the substrates are; they may also alter the metabolism of drugs used in psychiatry. The genes coding these two CYP enzymes occur in the population with variants that show extreme effects on their activity. For example, as a result of their genetic makeup, some individuals have no functioning CYP2D6 protein in their organism, while others have so much CYP2D6 that its function is enhanced 10-15 times. Studies in man show differences in the vulnerability for affective disorders among carriers of these CYP variants, and in brain activity obtained with modern neuroimaging methods. Furthermore, these CYPs are capable to metabolise drugs directly in the brain, thus changing the way in which they act in individual carriers of genetic variants. Hence, this genetic variation is not only a clue to the role of these CYPs in the brain, but may also have practical consequences for the treatment of mental disorders. This project brings together groups that work with laboratory animals that carry genetic variants of these two CYPs and groups that use neuroimaging methods to assay the effect of genetic variants naturally occurring in the population on brain function. These groups will work together to see if changes in the animals are also visible in neuroimaging data collected in the population. Using these different approaches together will help answering the question of the role of these CYPs in normal brain function and in affective disorders.
Program
Team Grant: Mental Disorders
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
289309
Name
Tyndale Rachel F
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Federal Ministry of Education and Research (Germany); Swedish Research Council (Sweden)
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Special Cases
Projecttitle
Role of genetic polymorphisms in drug metabolizing cytochrome P450 enzymes expressed in the brain for affective disorders
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$224,880
Cihrequipment2
$0
Programname2
Team Grant: Mental Disorders
Keyworddelim
Neurotransmitters; Psychiatry
Abstract
Cytochrome P450 (CYP) enzymes are an important class of drug metabolising enzymes, proteins that help eliminating external substances such as drugs or toxins that have been ingested or absorbed by the organism as well substances that are produced by the organism itself (endo¬genous substrates). Several findings suggest that two CYP enzymes, CYP2C19 and CYP2D6 have endogenous substrates, are in the brain, and may play directly a role in the genesis and course of affective illness, but as yet we do not know precisely what the substrates are; they may also alter the metabolism of drugs used in psychiatry. The genes coding these two CYP enzymes occur in the population with variants that show extreme effects on their activity. For example, as a result of their genetic makeup, some individuals have no functioning CYP2D6 protein in their organism, while others have so much CYP2D6 that its function is enhanced 10-15 times. Studies in man show differences in the vulnerability for affective disorders among carriers of these CYP variants, and in brain activity obtained with modern neuroimaging methods. Furthermore, these CYPs are capable to metabolise drugs directly in the brain, thus changing the way in which they act in individual carriers of genetic variants. Hence, this genetic variation is not only a clue to the role of these CYPs in the brain, but may also have practical consequences for the treatment of mental disorders. This project brings together groups that work with laboratory animals that carry genetic variants of these two CYPs and groups that use neuroimaging methods to assay the effect of genetic variants naturally occurring in the population on brain function. These groups will work together to see if changes in the animals are also visible in neuroimaging data collected in the population. Using these different approaches together will help answering the question of the role of these CYPs in normal brain function and in affective disorders.
Competitiondate
201306
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Tyndale, Rachel F
Approvedterm
3 ans 0 mois
Cihrcontribution2
Inst of Neurosc Mental Hlth &A~ $224,880~ $0~
University of Toronto - $224,880 Grant (2013-14) | Canada Spends